3 Programs
-
Exploring the Potential Role of PROTAC Estrogen Receptor Degraders in the Management of HR-Positive Metastatic Breast Cancer
-
-
E
-
E
-
-
E
-
E
-
-
Individualizing the Selection of First-Line Therapy for Patients with Hormone Receptor-Positive Metastatic Breast Cancer: Impact of Biomarkers and Existing Comorbidities
-
-
A
-
A
-
-
A
-
A
-
-
Optimizing the Selection of First-Line Therapy for Patients with Metastatic Non-Small Cell Lung Cancer and an ALK Rearrangement
-
-
J
-
J
-
-
J
-
J
-